Hancock Whitney’s Haemonetics HAE Stock Holding History

Hancock Whitney’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-17,076	Closed	-$1.46M	–	659
2023 Q4	$1.46M	Sell	17,076 -171	-1%	-$14.8K	0.05%	240
2023 Q3	$1.54M	Sell	17,247 -1,169	-6%	-$104K	0.06%	216
2023 Q2	$1.57M	Buy	18,416 +14	+0.1%	+$1.18K	0.06%	228
2023 Q1	$1.52M	Sell	18,402 -457	-2%	-$37K	0.06%	241
2022 Q4	$1.48M	Buy	+18,859	New	+$1.52M	0.06%	258
2020 Q1	–	Sell	-5,800	Closed	-$666K	–	859
2019 Q4	$666K	Hold	5,800	–	–	0.02%	512
2019 Q3	$732K	Sell	5,800 -1,400	-19%	-$178K	0.02%	507
2019 Q2	$866K	Hold	7,200	–	–	0.03%	496
2019 Q1	$630K	Buy	7,200 +400	+6%	+$36.4K	0.02%	562
2018 Q4	$680K	Hold	6,800	–	–	0.02%	498
2018 Q3	$779K	Hold	6,800	–	–	0.02%	532
2018 Q2	$610K	Sell	6,800 -2,700	-28%	-$228K	0.03%	413
2018 Q1	$695K	Sell	9,500 -5,400	-36%	-$370K	0.03%	394
2017 Q4	$865K	Buy	+14,900	New	+$785K	0.04%	371

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hancock Whitney's HAE Position: Q1 2024 in Review

Hancock Whitney sold out of Haemonetics (HAE) in Q1 2024, closing a stake of 17,076 shares — an estimated $1.46M sold.

Hancock Whitney first reported a position in HAE in Q4 2017 and held it in 14 quarters. The position peaked at $1.57M in Q2 2023. 298 funds tracked by Wall St. Rank hold HAE as of Q1 2024.

Hancock Whitney reported no remaining Haemonetics position as of Q1 2024 after selling out during the quarter.
Hancock Whitney sold 17,076 Haemonetics shares in Q1 2024, an estimated $1.46M.
Hancock Whitney first reported a position in Haemonetics in Q4 2017 and held it in 14 quarters.
Hancock Whitney's Haemonetics position peaked at $1.57M in Q2 2023.
298 funds tracked by Wall St. Rank held Haemonetics as of Q1 2024.

Based on Hancock Whitney's 13F filing for Q1 2024, filed 16 May 2024.